®

Our Mission

VETNOx LLC was formed to develop and commercialize nitric oxide based technologies for the companion animal health industry to treat cardio pulmonary disorders in a variety of species.

The VETNOx management team has worked together since 2005 when they formed ANOxA CORP, a veterinary translational and clinical research company to commercialize their pioneering equine product, which is a patented treatment for Exercise Induced Pulmonary Haemorrhage
(EIPH) in performance horses.  Working together they successfully developed it from concept stage to finished product, which led to licensing agreements to market and distribute it 
throughout North America, as well as Australia, New Zealand, Saudi Arabia, Singapore and China.

This same team has now created VETNOx to focus on maturing other related technologies that address major animal health issues and represent large potential markets.

VETNOx is currently developing PAPiSOLTM,, a multi use treatment platform for controlling pulmonary hypertension and it's associated conditions in various species including canine, feline and bovine.